Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ResMedASX:RMD +2.85%95 Days Sales Outstanding is 68.41 as of Jun. 2026, which is 9% above its 10-year median of 62.59. GuruFocus rates ASX:RMD with a GF Score™ of 95/100 and a GF Value™ of A$39.52 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 811 Medical Devices & Instruments companies, ResMed ranks better than 53.27% on this metric.
ResMed's average Accounts Receivable for the
three
months ended in Jun. 2026 was A$1,547 Mil. ResMed's Revenue for the
three
months ended in Jun. 2026 was A$2,063 Mil.
Hence, ResMed's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 68.41.
The historical rank and industry rank for ResMed's Days Sales Outstanding or its related term are showing as below:
ASX:RMD'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.35 Med: 62.59 Max: 73.52
Current: 62.85
During the past 13 years, ResMed's highest Days Sales Outstanding was 73.52. The lowest was 55.35. And the median was 62.59.
ASX:RMD's Days Sales Outstanding is ranked better than 53.27% of 811
companies
in the Medical Devices & Instruments industry
Industry Median: 65.38
vs ASX:RMD: 62.85
ResMed's Days Sales Outstanding
increased
from Jun. 2025 (66.18) to Jun. 2026 (68.41).
ResMed (ASX:RMD) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
ResMed Days Sales Outstanding Related Terms
ResMed Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for ResMed's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RMD vs MDLN, WST, BDX: Days Sales Outstanding Comparison
For the Medical Instruments & Supplies subindustry, ResMed's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where ResMed's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ResMed (ASX:RMD) has a Days Sales Outstanding of 68.41 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on ResMed and its competitors. This is near median its historical median of 62.59. Over the past decade, ResMed's Days Sales Outstanding has ranged from 55.35 to 73.52. According to the industry distribution chart, ResMed ranks #379 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 46.7%.
Is ResMed's Days Sales Outstanding too high?
ResMed's current Days Sales Outstanding of 68.41 is near median its 10-year median of 62.59. Over the past 10 years, this metric has ranged from a low of 55.35 to a high of 73.52. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.38. ResMed's value of 68.41 is 4.6% above this industry median. Based on the distribution chart, ResMed ranks #379 out of 811 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ResMed has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Days Sales Outstanding compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #379 out of 811 companies for Days Sales Outstanding. This puts ResMed in the upper half of its industry. The industry median Days Sales Outstanding is 65.38. ResMed's value of 68.41 is 4.6% above this benchmark. Historically, ResMed's own Days Sales Outstanding has ranged from 55.35 to 73.52 over the past decade. While the company's 10-year median is 62.59 vs. the industry median of 65.38, ResMed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.38, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current Days Sales Outstanding of 68.41 is 4.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current Days Sales Outstanding is 68.41, which is near median its own 10-year median of 62.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (ASX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is A$39.52, compared to a current price of A$31.37 — trading 20.6% below its estimated fair value. The current Days Sales Outstanding is 68.41, which is near median its 10-year median of 62.59 and 4.6% above the Medical Devices & Instruments industry median of 65.38. ResMed's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For ResMed (ASX:RMD), the current Days Sales Outstanding is 68.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (ASX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of A$31.37 is trading 20.6% below its estimated GF Value™ of A$39.52.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for ASX:RMD:
Days Sales Outstanding: 68.41 (near median its 10-year median of 62.59)
GF Value™: A$39.52 vs. price of A$31.37 (20.6% below fair value)
Industry Position: 4.6% above the Medical Devices & Instruments median (#379 of 811)
No single metric tells the full story. See the ASX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
95GF Score
Get the complete analysis for ASX:RMD
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RMD has been successfully added to your 
